Public advisory - Unauthorized Kobayashi Eyebon Eye Wash seized from Oceanbuy store and removed from website because it may pose serious health risks
OTTAWA, ON, Febr. 22, 2023 /CNW/ -
Brand: Kobayashi Eyebon Eye Wash
Summary
Product: Unauthorized health product labelled to contain a prescription drug
Issue: Health products ? Product safety
What to do: Do not use this product. Return it to your local pharmacy for proper disposal. Consult a health care professional if you have used this product and have health concerns. Prescription drugs can only be legally sold in Canada with a prescription. Buy your prescription drugs from licensed pharmacies only.
Images
Affected products
Product
Prescription drug on the label
Retailer
Kobayashi Eyebon Eye Wash, Cool format
Labelled in Japanese to contain aminocaproic acid
Oceanbuy
2600 John St., Unit #107
Markham, ON
Issue
Health Canada is warning consumers about an unauthorized health product, Kobayashi Eyebon Eye Wash, Cool format, which it seized from Oceanbuy, a store located in Markham ON, and removed from online sale. The unauthorized product was labelled in Japanese to contain aminocaproic acid, a prescription drug used to decrease bleeding in various clinical situations.
The product is promoted as an eye wash for contact lens users and for the prevention of eye disease.
Exposure to aminocaproic acid in the eye may affect the eye itself, and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, blurry or reduced vision, headache, dizziness, nausea, muscle weakness and skin rash.
Selling unauthorized health products in Canada is illegal. Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks. For example, they could contain high-risk ingredients, such as prescription drugs, additives or contaminants that may or may not be listed on the label. These ingredients could interact with other medications and foods. In addition, these products may not actually contain the active ingredients that consumers would expect them to contain to help maintain and improve their health.
Prescription drugs should only be used under the advice and supervision of a health care professional because they are used to treat specific conditions and may cause serious side effects.
What you should do
Do not use this product. Return the product to your local pharmacy for proper disposal.
Consult a health care professional if you have used this product and have health concerns.
Buy your prescription drugs only from licensed pharmacies.
Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...